Last reviewed · How we verify
Dose Expansion1
At a glance
| Generic name | Dose Expansion1 |
|---|---|
| Sponsor | GeneQuantum Healthcare (Suzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Abdominal Pain
- Fatigue
- Blood alkaline phosphatase increased
- Nasuea
- Decreased Appetite
- Back pain
- Vomiting
- Constipation
- Dizziness
- Tremor
- Disease progression
- Oedema Peripheral
Key clinical trials
- First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. (PHASE1)
- A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors (PHASE1)
- A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer (PHASE1, PHASE2)
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- Study of AXT-1003 in Subjects With Advanced Malignant Tumors. (PHASE1)
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dose Expansion1 CI brief — competitive landscape report
- Dose Expansion1 updates RSS · CI watch RSS
- GeneQuantum Healthcare (Suzhou) Co., Ltd. portfolio CI